5-Bromouracil

5-Bromouracil

SCHEMBL639925

O=C(O)CNCc1c[nH]c(=S)[nH]c1=O.O=c1[nH]cc(Br)c(=O)[nH]1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM3B Q7LBC6 1/20 0.38
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
MEN1 O00255 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
5-Bromouracil SCHEMBL5145285 0.94 ALDH1A1 (0.40) KMT2ATDP1KDM3BALDH1A1LMNA
SCHEMBL104627 0.87 KMT2A (0.48) KMT2ATDP1KDM3BALDH1A1MEN1
SCHEMBL101944 0.84 LMNA (0.41) LMNASMN1; SMN2
SCHEMBL9109566 0.74 KMT2A (0.46) KMT2ATDP1KDM3BALDH1A1MEN1
SCHEMBL7206108 0.73 CYP3A4 (0.33) LMNASMN1; SMN2
SCHEMBL28991875 0.71 GAA (0.46) LMNA
SCHEMBL18653592 0.71 KMT2A (0.37) KMT2ATDP1KDM3B
SCHEMBL31258192 0.71 LMNA (0.33) LMNASMN1; SMN2
SCHEMBL11739894 0.71
SCHEMBL4371043 0.71 CRBN (0.40) LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3484521-B1 POLY(L-LYSINE ISOPHTHALAMIDE) (PLP) POLYMERS WITH HYDROPHOBIC PENDANT CHAINS ALPHACELLS BIOTECHNOLOGIES LTD (GB) 2021-04-07 EP disclosed
EP-3430143-B1 INHIBITORS OF SRSF1 TO TREAT NEURODEGENERATIVE DISORDERS UNIV SHEFFIELD (GB) 2021-03-03 EP disclosed
EP-3484521-A1 POLY(L-LYSINE ISOPHTHALAMIDE) (PLP) POLYMERS WITH HYDROPHOBIC PENDANT CHAINS Imperial Innovations PLC (GB) 2019-05-22 EP disclosed
EP-3430143-A1 INHIBITORS OF SRSF1 TO TREAT NEURODEGENERATIVE DISORDERS University of Sheffield (GB) 2019-01-23 EP disclosed
WO-2018011580-A1 POLY(L-LYSINE ISOPHTHALAMIDE) (PLP) POLYMERS WITH HYDROPHOBIC PENDANT CHAINS IMPERIAL INNOVATIONS PLC (GB) 2018-01-18 WO disclosed
WO-2017207979-A1 INHIBITORS OF SRSF1 TO TREAT NEURODEGENERATIVE DISORDERS UNIVERSITY OF SHEFFIELD (GB) 2017-12-07 WO disclosed
EP-3207137-A1 PHARMACEUTICAL COMPOSITION FOR TREATING A VIRAL INFECTION London School Of Hygiene & Tropical Medicine (GB) 2017-08-23 EP disclosed
EP-3041480-A1 ANTI-VIRAL THERAPY The University of York (GB) 2016-07-13 EP disclosed
WO-2016059376-A1 PHARMACEUTICAL COMPOSITION FOR TREATING A VIRAL INFECTION LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE (GB) 2016-04-21 WO disclosed
WO-2015036737-A1 BIOMARKERS FOR DISEASE STRATIFICATION UNIVERSITY OF SHEFFIELD (GB) 2015-03-19 WO disclosed
WO-2011110838-A2 DIFFERENTIATION FACTOR PROCURE THERAPEUTICS LIMITED (GB) 2011-09-15 WO disclosed
WO-2011058300-A2 INDUCED PLURIPOTENT STEM CELL THE UNIVERSITY OF NOTTINGHAM (GB) 2011-05-19 WO disclosed
WO-2011036450-A2 SPLICE VARIANTS THE UNIVERSITY OF YORK (GB) 2011-03-31 WO disclosed
WO-2010100437-A9 PRODUCTION OF PROTEIN UNIVERSITY OF SHEFFIELD (GB) 2010-10-07 WO disclosed
WO-2010100437-A2 PRODUCTION OF PROTEIN UNIVERSITY OF SHEFFIELD (GB) 2010-09-10 WO disclosed
EP-2219654-A2 TREATMENT OF INFLAMMATORY DISEASES Medical Research Council (GB) 2010-08-25 EP disclosed
WO-2010089559-A1 CANCER DIAGNOSIS AND TREATMENT CIZZLE BIOTECHNOLOGY LIMITED (GB) 2010-08-12 WO disclosed
WO-2009053683-A2 TREATMENT OF INFLAMMATORY DISEASES MEDICAL RESEARCH COUNCIL (GB) 2009-04-30 WO disclosed
EP-1891216-A2 HYBRID INTERFERING RNA THE UNIVERSITY OF YORK (GB) 2008-02-27 EP disclosed
WO-2006125977-A2 HYBRID INTERFERING RNA THE UNIVERSITY OF YORK (GB) 2006-11-30 WO disclosed